Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration.

University Eye Clinic at the Centre for Ophthalmology of the Eberhard-Karls-University Tübingen, Schleichstrasse 12-15, 72076 Tuebingen, Germany.
Experimental Eye Research (Impact Factor: 3.02). 09/2006; 83(2):329-38. DOI: 10.1016/j.exer.2005.12.017
Source: PubMed

ABSTRACT Endostatin is an endogenous angiogenesis inhibitor which requires E-selectin for its antiangiogenic activity. The aim of this study was to investigate the expression of endostatin in human choroidal neovascular membranes (CNV) secondary to age-related macular degeneration (AMD) with regard to vascularization and proliferative activity. An interventional case series of 36 patients who underwent removal of CNV were retrospectively investigated. Thirty-six CNV were analyzed by light microscopic immunohistochemistry for the expression of CD34 (endothelial cells, EC), CD105 (activated EC), Ki-67 (cell proliferation), Cytokeratin 18 (epithelial cells), VEGF (vascular endothelial growth factor), E-selectin and endostatin. Donor eyes (n=7) including one with AMD were used as controls. Endostatin immunoreactivity was present in choroidal vessels of five as well as in the retinal pigment epithelium (RPE)-Bruch's membrane complex of two donor eyes without AMD. In one eye with AMD, endostatin was detected in RPE, Bruch's membrane and choroidal vessels. Ninety-two percent (33/36) of CNV disclosed endostatin staining. RPE-Bruch's membrane complex, choroidal vessels and stroma were positive in 50% (18/36), 72% (26/36), and 78% (28/36) of the membranes, respectively. Both control eyes and CNV expressed all the investigated markers except E-selectin being positive only in membranes. Endostatin, an endogenous angiogenesis inhibitor, is expressed in CNV and its therapeutic up-regulation may be a new strategy in the treatment of neovascular AMD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE:: To analyze intraocular growth factor and cytokine concentrations in eyes with different stages of age-related macular degeneration (AMD) compared with controls. METHODS:: The Clinical Age-Related Maculopathy Staging (CARMS) system was used for assignment of patients into the respective categories. Aqueous humor specimens were taken before cataract surgery in 21 controls (CARMS 1) and in 17 early (CARMS 2) and 16 intermediate (CARMS 3) AMD patients. In 18 neovascular (CARMS 5) AMD patients, specimens were taken immediately before anti-vascular endothelial growth factor intravitreal therapy. Luminex multiplex bead assays were conducted for endostatin, angiogenin, vascular endothelial growth factor, platelet-derived growth factor AA, placental growth factor, thrombospondin 2, and fibroblast growth factor a. RESULTS:: Vascular endothelial growth factor concentrations were elevated in CARMS 3 (P = 0.037) and tended to be elevated in CARMS 5 (P = 0.093), whereas levels in CARMS 2 (P = 0.425) were similar to CARMS 1. Platelet-derived growth factor levels were diminished in CARMS 2 (P = 0.020), with a trend to lower levels for CARMS 3 (P = 0.099) and CARMS 5 (P = 0.082) compared with CARMS 1. For CARMS 5, antiangiogenic endostatin was elevated (P < 0.002), while antiangiogenic thrombospondin 2 was reduced (P = 0.029). CONCLUSION:: Clinical Age-Related Maculopathy Staging 3 dry AMD was associated with higher vascular endothelial growth factor levels than CARMS 5 neovascular AMD. Therefore, intraocular vascular endothelial growth factor concentrations do not seem to reflect choroidal neovascularization activity in neovascular AMD directly. Platelet-derived growth factor was decreased in most forms of AMD. The antiangiogenic endostatin was exclusively elevated in neovascular AMD, while thrombospondin 2 was reduced. Age-related macular degeneration disease seems to be associated with a generally altered cytokine system.
    Retina (Philadelphia, Pa.) 03/2013; DOI:10.1097/IAE.0b013e318285cd9e · 3.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Retinal neovascularization is one of the leading causes for complete blindness in a number of diseases around the world. Endostar, a recently introduced recombinant human endostatin, has been considered as one of the most valuable anti-angiogenic agents. In this study, we demonstrate that Endostar inhibits both the proliferation of the choroid-retinal endothelial cells through limiting the progression of the cell cycle and their migration. Furthermore, Endostar induces the expression of the pigment epithelial-derived factor (PEDF) and suppresses the expression of the vascular endothelial growth factor (VEGF) and the fibroblast growth factor (FGF). Endostar also reduces the expression of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinases (MMPs) and vascular cell adhesion molecule-1 (VCAM-1). These findings reveal an integrated role of Endostar in the program of retinal vascular control and highlight its significant potential for broad clinical application.
    Molekuliarnaia biologiia 08/2010; 44(4):664-70. DOI:10.1134/S0026893310040138
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is a time of increasing hope for those afflicted with devastating retinal diseases. Less than a decade ago, very few options were available for someone newly diagnosed with exudative AMD, and none of the possible treatments involved pharmacological intervention. Today, numerous pharmacological therapies are available, both approved and off-label, along with a variety of other treatment modalities. This chapter reviews the history and outcomes of different treatment methods of posterior segment neovascularization, from the early days of pharmacological intervention to ongoing clinical trials. It then summarizes the various directions that future research may take in pursuing the treatment of pathological ocular angiogenesis.
    12/2007: pages 445-526;